Cargando…

Estimated Effectiveness of a Primary Cycle of Protein Recombinant Vaccine NVX-CoV2373 Against COVID-19

IMPORTANCE: Protein recombinant vaccine NVX-CoV2373 (Novavax) against COVID-19 was authorized for its use in adults in late 2021, but evidence on its estimated effectiveness in a general population is lacking. OBJECTIVE: To estimate vaccine effectiveness of a primary cycle with NVX-CoV2373 against S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mateo-Urdiales, Alberto, Sacco, Chiara, Petrone, Daniele, Bella, Antonino, Riccardo, Flavia, Del Manso, Martina, Bressi, Marco, Siddu, Andrea, Brusaferro, Silvio, Palamara, Anna Teresa, Rezza, Giovanni, Pezzotti, Patrizio, Fabiani, Massimo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Medical Association 2023
Materias:	Original Investigation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10551773/ https://www.ncbi.nlm.nih.gov/pubmed/37792377 http://dx.doi.org/10.1001/jamanetworkopen.2023.36854

Ejemplares similares

Protection against severe COVID-19 after second booster dose of adapted bivalent (original/Omicron BA.4-5) mRNA vaccine in persons ≥ 60 years, by time since infection, Italy, 12 September to 11 December 2022
por: Fabiani, Massimo, et al.
Publicado: (2023)

Relative effectiveness of a 2nd booster dose of COVID-19 mRNA vaccine up to four months post administration in individuals aged 80 years or more in Italy: A retrospective matched cohort study
por: Fabiani, Massimo, et al.
Publicado: (2023)

Relative effectiveness of bivalent Original/Omicron BA.4-5 mRNA vaccine in preventing severe COVID-19 in persons 60 years and above during SARS-CoV-2 Omicron XBB.1.5 and other XBB sublineages circulation, Italy, April to June 2023
por: Fabiani, Massimo, et al.
Publicado: (2023)

Effectiveness of BNT162b2 vaccine against SARS-CoV-2 infection and severe COVID-19 in children aged 5–11 years in Italy: a retrospective analysis of January–April, 2022
por: Sacco, Chiara, et al.
Publicado: (2022)

Risk and protective factors for SARS-CoV-2 reinfections, surveillance data, Italy, August 2021 to March 2022
por: Sacco, Chiara, et al.
Publicado: (2022)

Estimating averted COVID-19 cases, hospitalisations, intensive care unit admissions and deaths by COVID-19 vaccination, Italy, January−September 2021
por: Sacco, Chiara, et al.
Publicado: (2021)

Estimating SARS‐CoV‐2 infections and associated changes in COVID‐19 severity and fatality
por: Marziano, Valentina, et al.
Publicado: (2023)

Reduction of the risk of severe COVID-19 due to Omicron compared to Delta variant in Italy (November 2021 – February 2022)
por: Petrone, Daniele, et al.
Publicado: (2023)

Safety and Efficacy of NVX-CoV2373 Covid-19 Vaccine
por: Heath, Paul T., et al.
Publicado: (2021)

Immunogenicity of a Fourth Homologous Dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)

Novavax NVX-COV2373 triggers neutralization of Omicron sub-lineages
por: Bhiman, Jinal N., et al.
Publicado: (2023)

Epidemiological characteristics of COVID-19 cases in non-Italian nationals notified to the Italian surveillance system
por: Fabiani, Massimo, et al.
Publicado: (2021)

Efficacy and Safety of NVX-CoV2373 in Adults in the United States and Mexico
por: Dunkle, Lisa M., et al.
Publicado: (2021)

Protein vaccine NVX-CoV2373 elicits functional T cell immunity
por: Zhou, Pengcheng
Publicado: (2022)

Immunogenicity and safety of a fourth homologous dose of NVX-CoV2373
por: Alves, Katia, et al.
Publicado: (2023)

Myopericarditis following both BNT162b2 and NVX-CoV2373
por: Ahmad, Saima, et al.
Publicado: (2022)

Safety, Immunogenicity, and Efficacy of the NVX-CoV2373 COVID-19 Vaccine in Adolescents
por: Áñez, Germán, et al.
Publicado: (2023)

Impact of a Nationwide Lockdown on SARS-CoV-2 Transmissibility, Italy
por: Guzzetta, Giorgio, et al.
Publicado: (2021)

Impact of tiered restrictions on human activities and the epidemiology of the second wave of COVID-19 in Italy
por: Manica, Mattia, et al.
Publicado: (2021)

Initial impact of SARS-Cov-2 vaccination on healthcare workers in Italy– Update on the 28th of March 2021
por: Mateo-Urdiales, Alberto, et al.
Publicado: (2021)

The effect of COVID-19 vaccination in Italy and perspectives for living with the virus
por: Marziano, Valentina, et al.
Publicado: (2021)

Socioeconomic patterns and COVID-19 outcomes before, during and after the lockdown in Italy (2020)
por: Mateo-Urdiales, Alberto, et al.
Publicado: (2021)

COVID-19 response: effectiveness of weekly rapid risk assessments, Italy
por: Riccardo, Flavia, et al.
Publicado: (2022)

SARS-CoV-2 rS (NVX-CoV-2373) vaccine for prevention of COVID-19
Publicado: (2022)

Efficacy of the NVX-CoV2373 Covid-19 Vaccine Against the B.1.351 Variant
por: Shinde, Vivek, et al.
Publicado: (2021)

Safety of the NVX-CoV2373 COVID-19 vaccine in randomized placebo-controlled clinical trials
por: Smith, Katherine, et al.
Publicado: (2023)

Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants
por: Lyke, Kirsten E., et al.
Publicado: (2023)

A Case Report for Acute Myopericarditis After NVX-CoV2373 (Novavax(®)) COVID-19 Vaccination
por: Kim, Hyung Yoon, et al.
Publicado: (2022)

NVX-CoV2373, a protein-based vaccine against SARS-CoV-2 infection
por: Vohra-Miller, Sabina, et al.
Publicado: (2022)

Differences in the incidence and clinical outcomes of SARS-CoV-2 infection between Italian and non-Italian nationals using routine data
por: Fabiani, M., et al.
Publicado: (2022)

Safety surveillance of the NVX-CoV2373 COVID-19 vaccine among Koreans aged 18 years and over
por: Kim, Seontae, et al.
Publicado: (2023)

SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice
por: Tian, Jing-Hui, et al.
Publicado: (2021)

NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge
por: Guebre-Xabier, Mimi, et al.
Publicado: (2020)

NVX-CoV2373 vaccination induces functional SARS-CoV-2–specific CD4(+) and CD8(+) T cell responses
por: Rydyznski Moderbacher, Carolyn, et al.
Publicado: (2022)

Safety and Efficacy of the NVX-CoV2373 Coronavirus Disease 2019 Vaccine at Completion of the Placebo-Controlled Phase of a Randomized Controlled Trial
por: Heath, Paul T, et al.
Publicado: (2022)

NVX-CoV2373, un vaccin à sous-unités protéiques contre l’infection au SRAS-CoV-2
por: Vohra-Miller, Sabina, et al.
Publicado: (2022)

Serological response to Nuvaxovid (NVX-CoV2373) vaccine given as a fifth dose in non- and low-responder kidney transplant recipients
por: Nowak, Alexandra, et al.
Publicado: (2023)

Immunogenicity of NVX-CoV2373 in PREVENT-19: A Phase 3, Randomized, Placebo-Controlled Trial in Adults in the United States and Mexico
por: Áñez, Germán, et al.
Publicado: (2023)

Retrospective analysis of the Italian exit strategy from COVID-19 lockdown
por: Marziano, Valentina, et al.
Publicado: (2021)

Fab and Fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with Matrix-M vaccination
por: Gorman, Matthew J., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e56kkc191q7lca1l0i3heu69ob